Search the Newsreel

Amgen (AMGN) director Michael V. Drake granted 63.8764 shares in equity award

Amgen director Michael V. Drake was granted 63.8764 shares of common stock as compensation on August 7, 2026. This automatic award, valued at $0.00 per share, increases his direct holdings to 5,876.1633 shares, which includes 377 Dividend Equivalents linked to unvested Restricted Stock Units. …

Guggenheim raises Amgen stock price target to $388 on strong quarter

Guggenheim has increased its price target for Amgen Inc. (NASDAQ:AMGN) to $388 from $343, maintaining a Neutral rating after the company's strong second-quarter 2026 earnings. Amgen surpassed both Guggenheim's and consensus expectations, leading to revised fiscal year 2026 revenue and EPS estimates. Despite the …

Amgen Inc. (AMGN) Stock Analysis: Navigating a Strong Market Cap with High Return on Equity

Amgen Inc. (AMGN) is a significant player in the healthcare sector with a market capitalization of $221.79 billion. The company boasts a strong financial position, evidenced by its forward P/E ratio of 17.03, a remarkable return on equity of 91.47%, and robust free cash …

AMGEN INC : HSBC RAISES TARGET PRICE TO $445 FROM $425

HSBC has increased its target price for Amgen Inc. shares to $445, up from the previous $425. This adjustment reflects a positive outlook from the banking giant on the pharmaceutical company's stock.

Erste Group Bank Brokers Lower Earnings Estimates for Amgen

Erste Group Bank has lowered its FY2027 EPS estimate for Amgen to $23.50 from $23.58, while maintaining a "Hold" rating on the stock. This revised estimate still remains above the current full-year consensus of $22.78. Amgen reported strong Q2 results, with EPS of $6.29 …

Amgen Inc. (AMGN) Stock forecasts

Amgen, a leader in biotechnology, is experiencing broad-based growth despite biosimilar competition for Prolia, leading Morningstar to maintain its fair value assessment. The company's flagship drugs include Epogen, Aranesp, Neupogen, Neulasta, Enbrel, Otezla, and its first cancer therapeutic, Vectibix. The current stock price is …

Avity Investment Management Inc. Has $27.59 Million Stock Holdings in Amgen Inc. $AMGN

Avity Investment Management Inc. significantly increased its stake in Amgen Inc. by 5.3% in the second quarter, bringing its total holdings to 76,186 shares valued at approximately $27.59 million. Amgen recently reported strong second-quarter results, exceeding revenue and EPS expectations, and raised its 2026 …

Cardano Risk Management B.V. Sells 14,358 Shares of Amgen Inc. $AMGN

Cardano Risk Management B.V. has reduced its stake in Amgen Inc. by 5.2%, selling 14,358 shares and retaining 260,359 shares valued at $94.3 million. Amgen reported strong Q2 2026 results, exceeding revenue and EPS expectations, and raised its full-year earnings guidance despite discontinuing an …

Amgen (AMGN) Stock Sees Fair Value Lift After Q2 Beat And Analyst Target Hikes

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher …

Amgen Inc. Stock 12‑Month Price Target Raised to $378.67, Implies 6% Downside

Amgen Inc.'s average stock price target has been raised to $378.67 by 27 analysts, up from $376.44. This updated target implies a 6% potential downside based on the August 6 closing price. Despite the potential downside, the consensus rating from 35 analysts remains at …

Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?

Amgen's stock rose 6.7% after the European Medicines Agency's CHMP supported broader use of its drug Repatha for high-risk atherosclerotic cardiovascular disease patients in Europe. This potential expansion, driven by positive Phase 3 trial data, could significantly increase Repatha's eligible patient base. While strengthening …

Assenagon Asset Management S.A. Has $69.25 Million Position in Amgen Inc. $AMGN

Assenagon Asset Management S.A. significantly reduced its stake in Amgen Inc. by 44.5% during the second quarter, now holding 191,247 shares valued at $69.25 million. Despite this, other institutional investors have increased their positions, and analysts have set new price targets, with a consensus …

Amgen SVP & CCO Nancy Grygiel disposes of $1.19m in stock

Amgen's SVP & CCO, Nancy A. Grygiel, sold approximately $1.19 million worth of Amgen stock on August 6, 2026. This transaction was related to the exercise of non-qualified stock options, with the sales primarily covering the exercise price and withholding taxes. Following these transactions, …

Trade Tracker: Kevin Simpson buys more Amgen

Kevin Simpson, founder and CIO of Capital Wealth Planning, has increased his holdings in Amgen. He discussed his rationale for buying more shares at current price levels during an appearance on CNBC's 'Halftime Report.' The article primarily features a video clip of his explanation.

Amgen Inc. $AMGN Shares Acquired by Czech National Bank

The Czech National Bank increased its stake in Amgen Inc. by 4.8% in the second quarter, acquiring an additional 6,969 shares and bringing its total holdings to 153,622 shares valued at $55.6 million. This comes as Amgen reported strong second-quarter results, exceeding analyst expectations …

PensionDanmark Pensionsforsikringsaktieselskab Grows Stake in Amgen Inc. $AMGN

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Amgen Inc. by 12.3% in the second quarter, bringing its total ownership to 108,300 shares valued at approximately $39.2 million. This comes as Amgen reported strong quarterly results, with a 9.5% revenue increase and raised 2026 adjusted EPS …

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …

Amgen separates from weak drugmaker group, but 31% fair-value gap raises the bar

AMGN added 2.4% in the week to 31 July and sits only 3.2% below its 52-week high, with the Trend Signal active but volume confirmation still modest.

Trilogy Capital Inc. Has $302,000 Stock Holdings in Amgen Inc. $AMGN

Trilogy Capital Inc. significantly reduced its stake in Amgen Inc. by 91.8% in the second quarter, now holding 833 shares valued at approximately $302,000. Despite this, Amgen exceeded second-quarter expectations with adjusted earnings of $6.29 per share and revenue of $10.05 billion, and announced …

Amgen (AMGN) Stock Jumps As Raised Guidance Meets Mounting Risks

Amgen's stock jumped by 5% after its Q2 2026 earnings report, with revenue exceeding US$10 billion and basic EPS above US$4, leading to lifted full-year guidance. While new drugs and biosimilars are driving growth, the company faces significant risks including regulatory issues, product concentration, …

Amgen Inc (AMGN) (Q2 2026) Earnings Call Highlights: Revenue Surges Past $10 Billion, Guidance ...

Amgen Inc. reported strong Q2 2026 earnings with total revenues exceeding $10 billion, a 10% year-over-year increase, driven by double-digit sales growth in 22 products and significant contributions from key growth drivers like Repatha, EVENITY, and TEZSPIRE. The company also raised its 2026 revenue …

A Look at Amgen Inc (AMGN) After 4.6% Gain -- GF Value $353.96 v

Amgen Inc. (AMGN) shares recently rose 4.6% to $407.83, significantly above its GF Value™ of $353.96, indicating the stock is 15.2% overvalued. Despite a strong GF Score™ of 80/100, driven by high profitability and growth, its low momentum and financial strength rankings, alongside a …

Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, TD Cowen Analyst Says

TD Cowen has raised its price target for Amgen (NASDAQ:AMGN) to $452 from $420, maintaining a "Buy" rating and suggesting an 11.3% upside. This comes after Amgen exceeded Q2 earnings expectations with EPS of $6.29 and revenue of $10.05 billion, driven by newer products, …

Amgen Inc Stock (AMGN) Moved Up by 4.57% on Aug 5: Drivers Behind the Movement

Amgen Inc. (AMGN) saw its stock rise by 4.57% on August 5th, driven by a strong quarterly earnings report that surpassed expectations and increased full-year guidance. Positive clinical trial updates for its obesity drug MariTide also boosted investor confidence, with analysts raising price targets …

Amgen Extends Obesity Trial, Sharpening Its Long-Term Weight-Loss Bet

Amgen Inc. announced an update on its Phase 3 MARITIME-1-EXTENSION study for its obesity drug, maridebart cafraglutide (AMG 133 or MariTide). The trial aims to assess the long-term efficacy and safety of the drug in helping obese or overweight individuals maintain weight loss and …

Amgen stock hits all-time high at 398.65 USD

Amgen Inc. stock has reached an all-time high of $398.65, currently trading at $403.13, giving the biotechnology giant a market capitalization of $210.5 billion. The surge reflects investor confidence following strong performance, with the stock price increasing by 37.01% over the past year and …

Amgen (AMGN) Could Be 8% Overvalued Following Raised 2026 Guidance

Amgen (AMGN) reported strong Q2 2026 results, beating analyst expectations and raising its full-year revenue and earnings guidance. Despite a significant share price increase, Simply Wall St's narrative valuation suggests the stock is 8.3% overvalued at $390.02, with a fair value of $359.98, while …

Amgen gains after strong quarterly results and continued product momentum

Amgen's shares rose approximately 4% after the biotechnology company announced second-quarter 2026 results that exceeded Wall Street expectations. The company reported adjusted earnings per share of $6.29 and revenue of $10.05 billion, driven by a 10% year-over-year increase in total revenue and double-digit sales …

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Amgen reported strong second-quarter 2026 financial results, with total revenues increasing 10% to $10.1 billion and product sales growing 9%, driven by volume. The company saw significant growth in several key products like Repatha, EVENITY, and TEPEZZA, and provided updates on its extensive pipeline, …

Amgen (AMGN) Lifted 2026 Guidance, Is The Valuation Still Too Rich?

AMGEN INC : JEFFERIES RAISES TARGET PRICE TO $385 FROM $346

Jefferies has increased its target price for Amgen Inc. (AMGN) to $385 from $346. This information, provided by Reuters, indicates an analyst's revised valuation for the pharmaceutical company. The article also includes a disclaimer stating that the content reflects only the author's opinion and …

AMGEN INC : OPPENHEIMER RAISES TARGET PRICE TO $450 FROM $400

Oppenheimer has increased its target price for Amgen Inc. to $450 from $400. The article, sourced from Reuters, includes a disclaimer stating that its content reflects only the author's opinion and is not investment advice.

AMGEN INC : TRUIST SECURITIES RAISES TARGET PRICE TO $362 FROM $340

Truist Securities has increased its target price for Amgen Inc. (AMGN) from $340 to $362. This update reflects the analyst firm's revised outlook on the biotechnology company's financial prospects. The information is presented by Reuters.

AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class

Edelson Lechtzin LLP has launched a class action investigation into a data breach at Amgen Inc. The breach, identified in July 2026, involved unauthorized activity in cloud environments resulting in the exfiltration of patient protected health information and proprietary company data. The law firm …

Amgen raises 2026 EPS, revenue guidance as Q2 beats on both lines (AMGN:NASDAQ)

Amgen (AMGN) has raised its 2026 profit and revenue guidance after reporting strong Q2 financial results that exceeded expectations. The biopharma company now projects full-year non-GAAP EPS between $22.30 and $23.50, and revenue between $38 billion and $39.4 billion, both higher than previous estimates …

Highlights from Amgen's 2026 Second Quarter Earnings Report

Amgen released its 2026 second quarter earnings report, showcasing strong performance driven by key growth drivers that increased 26% year over year and accounted for nearly 70% of product sales. Chairman and CEO Robert A. Bradway expressed confidence in the company's ability to sustain …